MX69 | Dual Inhibitor of MDM2 and XIAP | CAS#1005264-47-0

MedKoo Cat#: 407438 | Name: MX69

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MX69 is a Dual Inhibitor of MDM2 and XIAP for Cancer Treatment.

Chemical Structure

MX69

CAS#1005264-47-0

Theoretical Analysis

MedKoo Cat#: 407438

Name: MX69

CAS#: 1005264-47-0

Chemical Formula: C27H26N2O4S

Exact Mass: 474.1613

Molecular Weight: 474.58

Elemental Analysis: C, 68.33; H, 5.52; N, 5.90; O, 13.48; S, 6.76

Price and Availability

Size	Price	Availability
100mg	USD 1,050.00	2 Weeks
200mg	USD 1,750.00	2 Weeks
500mg	USD 2,450.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 4,850.00	2 Weeks
5g	USD 8,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MX69; MX-69; MX 69.

IUPAC/Chemical Name

4-(8-(N-(2,3-dimethylphenyl)sulfamoyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl)benzoic acid

InChi Key

LAISWEODQAOXGJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C27H26N2O4S/c1-16-5-3-8-24(17(16)2)29-34(32,33)20-13-14-25-23(15-20)21-6-4-7-22(21)26(28-25)18-9-11-19(12-10-18)27(30)31/h3-6,8-15,21-22,26,28-29H,7H2,1-2H3,(H,30,31)

SMILES Code

O=S(C1=CC2=C(NC(C3=CC=C(C(O)=O)C=C3)C4C2C=CC4)C=C1)(NC5=C(C)C(C)=CC=C5)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

MX69 is an inhibitor of MDM2/XIAP, used for cancer treatment.

In vitro activity:

MX69 exhibited a significant cytotoxic effect on both ALL and NB lines, particularly those lines with MDM2 overexpression and a WT-p53 phenotype (Figure 6A and B). Figure 6C shows representative photomicrographs indicating cell growth inhibition and/or cell death in NB-1691 cells following treatment by MX69. Reference: Cancer Cell. 2016 Oct 10;30(4):623-636. https://pubmed.ncbi.nlm.nih.gov/27666947/

In vivo activity:

Here, this study administered MX69 intraperitoneally to high-fat diet-induced obesity (DIO) wild type C57BL/6 mice and found that MX69 could promote the body weight and white adipose tissue weight of DIO mice. Moreover, MX69 had no effects on glucose tolerance and insulin sensitivity in DIO mice. And MX69 treatment decreased the size of adipocytes and fat deposition in adipose tissue and inhibited 3T3-L1 preadipocytes differentiation. Mechanistically, MX69 inhibited the protein levels of MDM2 and the mRNA levels of genes related to adipogenesis and differentiation. Reference: Biochem Biophys Res Commun. 2022 Oct 15;625:9-15. https://pubmed.ncbi.nlm.nih.gov/35944364/

	Solvent	mg/mL	mM
Solubility
	DMSO	97.5	205.45
	Ethanol	41.0	86.39

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 474.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Faruq O, Zhao D, Shrestha M, Vecchione A, Zacksenhaus E, Chang H. Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel). 2022 Mar 21;14(6):1592. doi: 10.3390/cancers14061592. PMID: 35326742; PMCID: PMC8945937. 2. Gu L, Zhang H, Liu T, Zhou S, Du Y, Xiong J, Yi S, Qu CK, Fu H, Zhou M. Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell. 2016 Oct 10;30(4):623-636. doi: 10.1016/j.ccell.2016.08.015. Epub 2016 Sep 22. PMID: 27666947; PMCID: PMC5079537. 3. Zhao W, Yang J, Xie X, Li C, Zhang W, Chen E, Guo Y, Yan L, Fang F, Yao H, Liu X. A MDM2 inhibitor MX69 inhibits adipocytes adipogenesis and differentiation. Biochem Biophys Res Commun. 2022 Oct 15;625:9-15. doi: 10.1016/j.bbrc.2022.07.115. Epub 2022 Aug 2. PMID: 35944364.

In vitro protocol:

In vivo protocol:

1. Zhao W, Yang J, Xie X, Li C, Zhang W, Chen E, Guo Y, Yan L, Fang F, Yao H, Liu X. A MDM2 inhibitor MX69 inhibits adipocytes adipogenesis and differentiation. Biochem Biophys Res Commun. 2022 Oct 15;625:9-15. doi: 10.1016/j.bbrc.2022.07.115. Epub 2022 Aug 2. PMID: 35944364.

1: Gu L, Zhang H, Liu T, Zhou S, Du Y, Xiong J, Yi S, Qu CK, Fu H, Zhou M. Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell. 2016 Oct 10;30(4):623-636. doi: 10.1016/j.ccell.2016.08.015. Epub 2016 Sep 22. PubMed PMID: 27666947; PubMed Central PMCID: PMC5079537.

View History

Mycelianamide

MedKoo CAT#: 577847

CAS#: 22775-52-6